French Actos risk not seen with other diabetes drugs, and only in bladder cancer
This article was originally published in Scrip
Executive Summary
Not long after the furore over its tardy withdrawal of Servier's antidiabetic Mediator, the French medicines regulator Afssaps has now said it will suspend Takeda's diabetes drugs Actos and Competact, both formulated with pioglitazone. The move follows results of a French study indicating an increased risk of bladder cancer but comes before the European Medicines Agency has concluded its own benefit:risk review of the drugs. The Japanese drug regulator had not taken any action over Actos by close of business on 10 June, but Germany's Federal Institute for Drugs and Medical Devices has announced that it has suspended the use of the drug.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.